trial

Zyprexa and Task Engagement in Schizophrenia

NCTId NCT00440843
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Withdrawn
Enrollment 0 (actual)
Sponsored by VA Connecticut Healthcare System
Primary completion 2012-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2007-02
Primary completion
2012-06
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
OlanzapineTypicals

Sponsors

VA Connecticut Healthcare SystemLead Sponsor
Clinical Trials Network of Columbia U, Cornell U, and NY Presbyterian HospitalCollaborator
Eli Lilly and CompanyCollaborator

Investigators

1
Jimmy Choi, Psy.D.Principal Investigator

Sites

1 total
New York, United States

Linked catalysts

1
Zyprexa and Task Engagement in Schizophrenia — primary completion2012-06

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE3
Primary Completion Date
2012-06
Status
WITHDRAWN
relationships
The graph out of here
drug
Olanzapine
drug
Typicals
drug
lead_sponsor
VA Connecticut Healthcare System
company
collaborator
Clinical Trials Network of Columbia U, Cornell U, and NY Presbyterian Hospital
company
Eli Lilly and Company
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Jimmy Choi, Psy.D.
person